Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. LDOS
8. HUM
9. CSCO
10. KTOS

Go back to Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c, Revenues Beat

February 28, 2019 4:27 PM EST

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $26.84 million versus the consensus estimate of $22.51 million.

ST-920 IND acceptance: The U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug application (IND) for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Sangamo expects to initiate the Phase 1/2 clinical trial evaluating ST-920 later this year.WORLDSymposium presentations: At the WORLDSymposium earlier in February, Sangamo presented... More